2025年上半年的医药板块,如同一场蓄力已久的春雨,终于迎来了酣畅淋漓的落地。A股和港股医药生物指数涨幅居前,板块整体估值虽已回升至5年内72%的分位数,但若将视线投向医保政策优化、创新回报兑现、支付端变革等深层动力,便会发现这场行情的“水位”远未触及天花板——它更像是一条刚刚冲出山涧的溪流,主升浪的奔涌仍在中长期延续。政策东风:从“控费”到“赋能”的医保改革过去几年,医保政策经历了从“严控支出”...
Source Link2025年上半年的医药板块,如同一场蓄力已久的春雨,终于迎来了酣畅淋漓的落地。A股和港股医药生物指数涨幅居前,板块整体估值虽已回升至5年内72%的分位数,但若将视线投向医保政策优化、创新回报兑现、支付端变革等深层动力,便会发现这场行情的“水位”远未触及天花板——它更像是一条刚刚冲出山涧的溪流,主升浪的奔涌仍在中长期延续。政策东风:从“控费”到“赋能”的医保改革过去几年,医保政策经历了从“严控支出”...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.